vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Natural Grocers by Vitamin Cottage, Inc. (NGVC). Click either name above to swap in a different company.
Natural Grocers by Vitamin Cottage, Inc. is the larger business by last-quarter revenue ($335.6M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 3.4%, a 93.0% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 1.6%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 4.4%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Natural Grocers by Vitamin Cottage, Inc. is a U.S.-based specialty retail chain that offers certified organic groceries, dietary supplements, natural personal care items, and eco-friendly household products. It serves health-conscious consumers across multiple U.S. states, following strict quality standards that exclude artificial preservatives, colors, flavors and harmful additives.
ACAD vs NGVC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $335.6M |
| Net Profit | $273.6M | $11.3M |
| Gross Margin | 90.8% | 29.5% |
| Operating Margin | 6.1% | 4.4% |
| Net Margin | 96.3% | 3.4% |
| Revenue YoY | 9.4% | 1.6% |
| Net Profit YoY | 90.3% | 14.0% |
| EPS (diluted) | $1.61 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $335.6M | ||
| Q3 25 | $278.6M | $336.1M | ||
| Q2 25 | $264.6M | $328.7M | ||
| Q1 25 | $244.3M | $335.8M | ||
| Q4 24 | $259.6M | $330.2M | ||
| Q3 24 | $250.4M | $322.7M | ||
| Q2 24 | $242.0M | $309.1M | ||
| Q1 24 | $205.8M | $308.1M |
| Q4 25 | $273.6M | $11.3M | ||
| Q3 25 | $71.8M | $11.8M | ||
| Q2 25 | $26.7M | $11.6M | ||
| Q1 25 | $19.0M | $13.1M | ||
| Q4 24 | $143.7M | $9.9M | ||
| Q3 24 | $32.8M | $9.0M | ||
| Q2 24 | $33.4M | $9.2M | ||
| Q1 24 | $16.6M | $8.0M |
| Q4 25 | 90.8% | 29.5% | ||
| Q3 25 | 92.2% | 29.5% | ||
| Q2 25 | 92.2% | 29.9% | ||
| Q1 25 | 91.7% | 30.3% | ||
| Q4 24 | 91.6% | 29.9% | ||
| Q3 24 | 92.5% | 29.6% | ||
| Q2 24 | 92.5% | 29.2% | ||
| Q1 24 | 88.8% | 29.3% |
| Q4 25 | 6.1% | 4.4% | ||
| Q3 25 | 12.8% | 4.6% | ||
| Q2 25 | 12.2% | 4.7% | ||
| Q1 25 | 7.9% | 5.2% | ||
| Q4 24 | 59.1% | 4.0% | ||
| Q3 24 | 12.6% | 3.7% | ||
| Q2 24 | 12.6% | 4.2% | ||
| Q1 24 | 7.4% | 3.7% |
| Q4 25 | 96.3% | 3.4% | ||
| Q3 25 | 25.8% | 3.5% | ||
| Q2 25 | 10.1% | 3.5% | ||
| Q1 25 | 7.8% | 3.9% | ||
| Q4 24 | 55.4% | 3.0% | ||
| Q3 24 | 13.1% | 2.8% | ||
| Q2 24 | 13.8% | 3.0% | ||
| Q1 24 | 8.0% | 2.6% |
| Q4 25 | $1.61 | $0.49 | ||
| Q3 25 | $0.42 | $0.51 | ||
| Q2 25 | $0.16 | $0.50 | ||
| Q1 25 | $0.11 | $0.56 | ||
| Q4 24 | $0.86 | $0.43 | ||
| Q3 24 | $0.20 | $0.38 | ||
| Q2 24 | $0.20 | $0.40 | ||
| Q1 24 | $0.10 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $23.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $220.0M |
| Total Assets | $1.6B | $668.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $23.2M | ||
| Q3 25 | $258.0M | $17.1M | ||
| Q2 25 | $253.6M | $13.2M | ||
| Q1 25 | $217.7M | $21.2M | ||
| Q4 24 | $319.6M | $6.3M | ||
| Q3 24 | $155.1M | $8.9M | ||
| Q2 24 | $177.1M | $13.9M | ||
| Q1 24 | $204.7M | $11.0M |
| Q4 25 | $1.2B | $220.0M | ||
| Q3 25 | $917.3M | $212.4M | ||
| Q2 25 | $822.4M | $202.5M | ||
| Q1 25 | $765.2M | $193.0M | ||
| Q4 24 | $732.8M | $181.9M | ||
| Q3 24 | $577.2M | $174.3M | ||
| Q2 24 | $516.7M | $167.8M | ||
| Q1 24 | $464.0M | $160.0M |
| Q4 25 | $1.6B | $668.6M | ||
| Q3 25 | $1.3B | $670.5M | ||
| Q2 25 | $1.2B | $659.0M | ||
| Q1 25 | $1.1B | $664.6M | ||
| Q4 24 | $1.2B | $648.9M | ||
| Q3 24 | $976.9M | $655.5M | ||
| Q2 24 | $914.1M | $654.4M | ||
| Q1 24 | $855.1M | $656.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $21.1M |
| Free Cash FlowOCF − Capex | — | $11.6M |
| FCF MarginFCF / Revenue | — | 3.4% |
| Capex IntensityCapex / Revenue | — | 2.9% |
| Cash ConversionOCF / Net Profit | -0.18× | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | $42.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $21.1M | ||
| Q3 25 | $74.3M | $15.6M | ||
| Q2 25 | $64.0M | $2.9M | ||
| Q1 25 | $20.3M | $34.1M | ||
| Q4 24 | $40.4M | $2.7M | ||
| Q3 24 | $63.2M | $24.5M | ||
| Q2 24 | $25.0M | $12.4M | ||
| Q1 24 | $29.1M | $20.2M |
| Q4 25 | — | $11.6M | ||
| Q3 25 | $73.9M | $7.5M | ||
| Q2 25 | — | $-4.2M | ||
| Q1 25 | — | $27.6M | ||
| Q4 24 | — | $-6.9M | ||
| Q3 24 | $63.2M | $18.0M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $9.8M |
| Q4 25 | — | 3.4% | ||
| Q3 25 | 26.5% | 2.2% | ||
| Q2 25 | — | -1.3% | ||
| Q1 25 | — | 8.2% | ||
| Q4 24 | — | -2.1% | ||
| Q3 24 | 25.2% | 5.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 3.2% |
| Q4 25 | — | 2.9% | ||
| Q3 25 | 0.1% | 2.4% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 1.9% | ||
| Q4 24 | — | 2.9% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 3.4% |
| Q4 25 | -0.18× | 1.86× | ||
| Q3 25 | 1.03× | 1.32× | ||
| Q2 25 | 2.40× | 0.25× | ||
| Q1 25 | 1.07× | 2.60× | ||
| Q4 24 | 0.28× | 0.27× | ||
| Q3 24 | 1.93× | 2.72× | ||
| Q2 24 | 0.75× | 1.35× | ||
| Q1 24 | 1.76× | 2.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
